*Five Years Citation in Google scholar (2016 - 2020) is. 1451*   *    IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *       

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Intravitreal Tissue Plasminogen Activator in Diabetic Vitreous Hemorrhage

Author: NIYOUSHA REZA, AHOOR MOHAMMAD HOSEIN, HASHEMI HESAMSADAT, EFTEKHARI MILANI AMIR , HASANPOOR NARGES, NAJAFI AMIN
Abstract: Background and Purpose: Vitreous hemorrhage is one of the most common complications of diabetic retinopathy that causes significant visual impairment. So, the aim of this research was evaluation of the effect of intravitreal tissue plasminogen activator (tPA) on diabetic vitreous hemorrhage. Material and Methods: This is a Double blinded randomized clinical trial on 15 patients with diabetic vitreous hemorrhage received single dose of 80µ in 0.1 ml tPA intravitrealy and 15 patients received 1.25 mg intravitreal Bevacizumab (IVB). Visual acuity and vitreous hemorrhage grading before and after intervention were evaluated as main outcome. Results: 30 patients completed our study (15 patients in each group). Primary characteristics of two group had no differences significantly. Visual acuity before intervention had no significant difference between groups. After intervention visual acuity was significantly better in IVB group compared to tPA group (P=0.027). There was no significant difference between groups in term of vitreous hemorrhage grading before and after intervention. Visual acuity and grading of vitreous hemorrhage improved after intervention compared to the baseline in both groups. Conclusion: TPA is statistically effective in resolution of diabetic vitreous hemorrhage however, its effect is less than bevacizumab and its clinical benefit comparing to observation may need more evaluation.
Keyword: Intravitreal Tissue Plasminogen Activator, Diabetic Vitreous Hemorrhage.
Download: Request For Article
 




ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free